Published in J Transl Med on September 22, 2016
Cancer genome landscapes. Science (2013) 25.33
Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science (2015) 21.42
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Membrane vesicles as conveyors of immune responses. Nat Rev Immunol (2009) 14.72
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Cancer immunotherapy comes of age. Nature (2011) 12.35
Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 9.46
Macrophage biology in development, homeostasis and disease. Nature (2013) 8.28
Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol (1994) 8.16
MHC ligands and peptide motifs: first listing. Immunogenetics (1995) 7.78
Exosomes--vesicular carriers for intercellular communication. Curr Opin Cell Biol (2009) 6.96
Cancer immunology. N Engl J Med (2008) 5.22
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res (2003) 5.04
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Benefits and Harms of Breast Cancer Screening: A Systematic Review. JAMA (2015) 3.36
Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol (2008) 3.17
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature (2015) 2.71
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
Development and maintenance of regulatory T cells. Immunity (2013) 2.61
Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet (2014) 2.57
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
Substantial contribution of extrinsic risk factors to cancer development. Nature (2015) 2.46
Applying what we know to accelerate cancer prevention. Sci Transl Med (2012) 2.43
Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol (2013) 1.89
Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer (2002) 1.34
Therapeutic cancer vaccines. J Clin Invest (2015) 1.23
A new era in anticancer peptide vaccines. Cancer (2010) 1.18
Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol (2010) 1.09
Active surveillance for clinically localized prostate cancer--a systematic review. J Surg Oncol (2014) 1.09
Characterization of human thymic exosomes. PLoS One (2013) 1.05
Extracellular vesicle transfer of cancer pathogenic components. Cancer Sci (2016) 1.01
Immunogenicity of autoantigens. BMC Genomics (2011) 0.97
Human cancer regression antigens. Curr Opin Immunol (2013) 0.96
Mechanisms of epithelial wound detection. Trends Cell Biol (2015) 0.96
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
Cancer development and its natural history. A cancer prevention perspective. Cancer (1988) 0.90
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Mol Oncol (2015) 0.88
Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer (2012) 0.88
Immunogenic peptide discovery in cancer genomes. Curr Opin Genet Dev (2015) 0.85
A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep (2011) 0.85
Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions. Hum Pathol (2015) 0.82
miR-16 promotes the apoptosis of human cancer cells by targeting FEAT. BMC Cancer (2015) 0.81
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med (2015) 0.80
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol (2016) 0.79
METTL13 is downregulated in bladder carcinoma and suppresses cell proliferation, migration and invasion. Sci Rep (2016) 0.78